secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193125-24-002894
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics provides 2024 outlook; cash $76.3M, runway into late 2025; SPR720 Phase 2a data due 2H 2024
--------------------------------------------------------------------------------

- Preliminary cash and cash equivalents of $76.3M as of Dec 31, 2023 (unaudited).
- Cash plus $95M in GSK development milestones expected to fund operations into late 2025.
- PIVOT-PO Phase 3 trial of tebipenem HBr for cUTI initiated; target enrollment ~2,648 patients; completion expected 2H 2025.
- SPR720 Phase 2a topline data for NTM-PD expected in second half of 2024.
- Company entitled to $95M in development milestones from GSK, payable in four equal installments over two years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524002894/0001193125-24-002894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524002894/d901241d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-002894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer